-
Trading Resumed In Gen-Probe, Code T7 (GPRO)
Thursday, April 28, 2011 - 10:51am | 54Trading has resumed in Gen-Probe (NASDAQ: GPRO). Earlier, the NASDAQ had announced that quotations resumed in the affected security, but trading remained paused. This halt was coded as T7 by the NASDAQ stock exchange. Any time for trade resumption will be provided below, if available. 10:50 AM
-
Trading Halted: Gen-Probe Incorporated, Circuit Breaker
Thursday, April 28, 2011 - 10:47am | 16Trading Halted: Gen-Probe Incorporated (NASDAQ: GPRO), Circuit Breaker
-
Varian Medical Posted Solid 2Q Results, Jefferies Reports (VAR)
Thursday, April 28, 2011 - 9:44am | 88In a recent report by Jefferies, Varian Medical (NYSE: VAR) posted solid second quarter results. According to Jefferies, “VAR reported solid FQ2 results with revenues and EPS slightly ahead of both our and Street estimates.” Varian Medical also saw net order growth. “Total net orders came in at $...
-
Top five companies Stocks in the Specialty Chemicals industry- ROC, NLC, CYT, FOE, ECL
Thursday, April 28, 2011 - 9:14am | 12001) Rockwood Holdings (NYSE:ROC) ranks first with a gain of 10.09%- The company reported net income of $178 million, or $2.24 a share, for the three months ended March 31. That compares with net income of $36.9 million, or 48 cents a share, in the same quarter last year. The results included a $...
-
Invacare Corp Reports EPS of $0.32 vs. $0.25 Estimate; Revenues $428.5M vs. $406.25M Estimate (IVC)
Thursday, April 28, 2011 - 8:55am | 22Invacare Corp (NYSE: IVC) Reports EPS of $0.32 vs. $0.25 Estimate; Revenues $428.5M vs. $406.25M Estimate
-
Integra LifeSciences Reports EPS of $0.38 vs. $0.66 Estimate; Revenues $181M vs. $180.84M Estimate (IART)
Thursday, April 28, 2011 - 8:54am | 22Integra LifeSciences (NASDAQ: IART) Reports EPS of $0.38 vs. $0.66 Estimate; Revenues $181M vs. $180.84M Estimate
-
CONMED Corporation Reports EPS of $0.31 vs. $0.31 Estimate; Revenues $183.5M vs. $181.85M Estimate (CNMD)
Thursday, April 28, 2011 - 8:46am | 22CONMED Corporation (NASDAQ: CNMD) Reports EPS of $0.31 vs. $0.31 Estimate; Revenues $183.5M vs. $181.85M Estimate
-
CryoLife Reports EPS of $0.09 vs. $0.08 Estimate; Revenues $30.2M vs. $30.56M Estimate
Thursday, April 28, 2011 - 8:10am | 21CryoLife (NYSE: CRY) Reports EPS of $0.09 vs. $0.08 Estimate; Revenues $30.2M vs. $30.56M Estimate
-
Cryolife Guides 2011 EPS $0.26-$0.30 (CRY)
Thursday, April 28, 2011 - 8:10am | 14Cryolife (NYSE: CRY) Guides 2011 EPS $0.26-$0.30
-
J.P. Morgan Raises PT To $68 On VAR
Thursday, April 28, 2011 - 7:49am | 125J.P. Morgan, following a strong F2Q11, is raising its price target on Varian Medical (NYSE: VAR) from $65 to $68. Says J.P. Morgan, in the report, “Varian reported a better than expected orders quarter and beat both our and consensus EPS estimate by $0.01. TrueBeam orders accelerated from F1Q, a...
-
Zimmer Holdings Reports EPS of $1.19 vs. $1.12 Estimate; Revenues $1.16B vs. $1.09B Estimate
Thursday, April 28, 2011 - 7:29am | 22Zimmer Holdings (NYSE: ZMH) Reports EPS of $1.19 vs. $1.12 Estimate; Revenues $1.16B vs. $1.09B Estimate
-
Invacare Corporation Reports Improved Earnings and Strong Organic Net Sales Growth for the First Quarter of 2011
Thursday, April 28, 2011 - 7:07am | 116Invacare Corporation (NYSE: IVC) today announced its financial results for the quarter ended March 31, 2011. Earnings per share on a GAAP basis increased 156% for the quarter to $0.23 versus $0.09 last year. The results were negatively impacted by $0.15 per share ($4.9 million net after-tax...
-
JP Morgan Raises PT On Varian medical To $68
Thursday, April 28, 2011 - 6:30am | 27JP Morgan has raised the price target on Varian Medical (NYSE: VAR) from $65 to $68 and maintains its Neutral rating.
-
Deutsche Bank Raises PT On Becton Dickinson To $88
Thursday, April 28, 2011 - 6:22am | 27Deutsche Bank has raised the price target on Becton Dickinson (NYSE: BDX) from $86 to $88 and maintains its Hold rating.
-
Mad Money Lightning Round: Cramer Likes Apple (MDT, STJ, ABT, MNRO, CMI, WFC, UA, AAPL, AHD)
Thursday, April 28, 2011 - 2:31am | 256On CNBC's Mad Money, Jim Cramer said during the Lightning Round that Medtronic (NYSE: MDT): is “not an exciting stock. I like St Jude Medical (NYSE: STJ). I don't see any catalyst. I think Abbott Laboratories (NYSE: ABT) is better, too." He said that Monro Muffler (NASDAQ: MNRO) “does not belong...